Cite
HARVARD Citation
Pennipede, D. et al. (2021). Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM). European journal of haematology. pp. 602-608. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Pennipede, D. et al. (2021). Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM). European journal of haematology. pp. 602-608. [Online].